SK281095B6 - Hydroxynaftoát-4-hydroxy-alfa1-[[[6-(4- -fenylbutoxy)hexyl]amino]metyl]-1,3-benzéndimetanolu vhodný na mikronizáciu, spôsob jeho výroby, farmaceutická dávkovacia forma s jeho obsahom a jeho použitie - Google Patents

Hydroxynaftoát-4-hydroxy-alfa1-[[[6-(4- -fenylbutoxy)hexyl]amino]metyl]-1,3-benzéndimetanolu vhodný na mikronizáciu, spôsob jeho výroby, farmaceutická dávkovacia forma s jeho obsahom a jeho použitie Download PDF

Info

Publication number
SK281095B6
SK281095B6 SK545-93A SK54593A SK281095B6 SK 281095 B6 SK281095 B6 SK 281095B6 SK 54593 A SK54593 A SK 54593A SK 281095 B6 SK281095 B6 SK 281095B6
Authority
SK
Slovakia
Prior art keywords
organic solvent
hydroxynaphthoate
microcrystals
mixture
water
Prior art date
Application number
SK545-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK54593A3 (en
Inventor
Steven Frederick Beach
David William Stuart Latham
Tony Gordon Roberts
Colin Brian Sidgwick
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SK54593A3 publication Critical patent/SK54593A3/sk
Publication of SK281095B6 publication Critical patent/SK281095B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
SK545-93A 1990-11-29 1991-11-28 Hydroxynaftoát-4-hydroxy-alfa1-[[[6-(4- -fenylbutoxy)hexyl]amino]metyl]-1,3-benzéndimetanolu vhodný na mikronizáciu, spôsob jeho výroby, farmaceutická dávkovacia forma s jeho obsahom a jeho použitie SK281095B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909026005A GB9026005D0 (en) 1990-11-29 1990-11-29 Drug material suitable for micronisation
PCT/GB1991/002108 WO1992009557A1 (en) 1990-11-29 1991-11-28 Benzenedimethanol suitable for micronisation

Publications (2)

Publication Number Publication Date
SK54593A3 SK54593A3 (en) 1993-10-06
SK281095B6 true SK281095B6 (sk) 2000-11-07

Family

ID=10686212

Family Applications (1)

Application Number Title Priority Date Filing Date
SK545-93A SK281095B6 (sk) 1990-11-29 1991-11-28 Hydroxynaftoát-4-hydroxy-alfa1-[[[6-(4- -fenylbutoxy)hexyl]amino]metyl]-1,3-benzéndimetanolu vhodný na mikronizáciu, spôsob jeho výroby, farmaceutická dávkovacia forma s jeho obsahom a jeho použitie

Country Status (27)

Country Link
US (1) US5380922A (el)
EP (2) EP0639176B1 (el)
JP (1) JP3375626B2 (el)
KR (1) KR100192196B1 (el)
AT (1) ATE144244T1 (el)
AU (1) AU644505B2 (el)
BG (1) BG61340B1 (el)
CA (1) CA2099586C (el)
CY (1) CY2009A (el)
CZ (1) CZ282996B6 (el)
DE (1) DE69122780T2 (el)
DK (1) DK0639176T3 (el)
ES (1) ES2093812T3 (el)
FI (2) FI118155B (el)
GB (1) GB9026005D0 (el)
GR (1) GR3022088T3 (el)
HK (1) HK78997A (el)
HU (1) HU218205B (el)
IE (1) IE914146A1 (el)
OA (2) OA09861A (el)
PL (2) PL167976B1 (el)
RU (2) RU2116293C1 (el)
SG (1) SG49741A1 (el)
SK (1) SK281095B6 (el)
TW (1) TW309425B (el)
WO (1) WO1992009557A1 (el)
ZA (1) ZA919401B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
AU1229892A (en) * 1992-02-11 1993-09-03 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
EP1169019B1 (en) 1999-04-14 2003-02-26 Glaxo Group Limited Pharmaceutical aerosol formulation
WO2002026239A1 (en) 2000-09-26 2002-04-04 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
EP2127641A1 (en) * 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
KR101100614B1 (ko) 2010-09-20 2011-12-29 한국수력원자력 주식회사 농축폐액 건조물의 펠렛화 장치 및 방법과 이를 이용한 유리조성개발 방법
WO2016142582A1 (en) 2015-03-11 2016-09-15 Fermion Oy Process for the preparation of crystalline salmeterol and its xinafoate salt

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation

Also Published As

Publication number Publication date
CZ101993A3 (en) 1994-01-19
EP0639176B1 (en) 1996-10-16
HK78997A (en) 1997-06-20
EP0639176A1 (en) 1995-02-22
FI118155B (fi) 2007-07-31
IE914146A1 (en) 1992-06-03
DE69122780T2 (de) 1997-02-20
FI982081A0 (fi) 1998-09-28
ZA919401B (en) 1992-07-29
HU9301568D0 (en) 1993-09-28
SG49741A1 (en) 1998-06-15
US5380922A (en) 1995-01-10
HUT64219A (en) 1993-12-28
GR3022088T3 (en) 1997-03-31
ATE144244T1 (de) 1996-11-15
BG97767A (bg) 1994-12-02
FI118203B (fi) 2007-08-31
DE69122780D1 (de) 1996-11-21
HU218205B (hu) 2000-06-28
JP3375626B2 (ja) 2003-02-10
OA09861A (en) 1994-08-15
EP0571669B1 (en) 1996-03-06
BG61340B1 (en) 1997-06-30
RU2116293C1 (ru) 1998-07-27
PL169722B1 (pl) 1996-08-30
CA2099586A1 (en) 1992-05-30
CY2009A (en) 1998-02-20
ES2093812T3 (es) 1997-01-01
DK0639176T3 (da) 1996-12-23
PL167976B1 (pl) 1995-12-30
AU9040291A (en) 1992-06-25
AU644505B2 (en) 1993-12-09
FI982081A (fi) 1998-09-28
KR100192196B1 (en) 1999-06-15
TW309425B (el) 1997-07-01
CA2099586C (en) 2002-06-25
OA10024A (en) 1996-10-14
JPH06503082A (ja) 1994-04-07
CZ282996B6 (cs) 1997-12-17
EP0571669A1 (en) 1993-12-01
FI932422A (fi) 1993-05-27
FI932422A0 (fi) 1993-05-27
SK54593A3 (en) 1993-10-06
RU2197475C2 (ru) 2003-01-27
WO1992009557A1 (en) 1992-06-11
GB9026005D0 (en) 1991-01-16

Similar Documents

Publication Publication Date Title
IE910222A1 (en) Aerosol carriers
NL8204013A (nl) Steroid en farmaceutisch preparaat alsmede werkwijze voor het bereiden daarvan.
JP4512203B2 (ja) フォルモテロールを含む０．２８から０．３８ｇ／ｍｌのかさ密度を有する吸入用新規製剤
SK281095B6 (sk) Hydroxynaftoát-4-hydroxy-alfa1-[[[6-(4- -fenylbutoxy)hexyl]amino]metyl]-1,3-benzéndimetanolu vhodný na mikronizáciu, spôsob jeho výroby, farmaceutická dávkovacia forma s jeho obsahom a jeho použitie
KR102163368B1 (ko) 플루티카손 프로피오네이트 형태 1의 제조 방법
Westmeier et al. Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment
BR112021008732A2 (pt) ingredientes farmacêuticos amorfos ativos compreendendo carbonato de magnésio mesoporoso substancialmente amorfo
CN112972384B (zh) 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
US20040247689A1 (en) Process for preparing a pharmaceutical active ingredient with high specific surface area
EP2303232B1 (en) Micronisable form of salmeterol xinafoate
AP323A (en) Drug material suitable for micronisation.
SI9200252A (sl) Zdravilni material, primeren za mikronizacijo
WO1993016031A1 (en) Benzenedimethanol derivative suitable for micronisation
CN1056974C (zh) 适宜于微粒化的药物材料的制备方法
IL101798A (en) 1-hydroxy-2-naphthalene carboxylate (hydroxynaphthoate) salt of 4-hydroxy- alpha1-[[[6-4-phenylbutoxy) hexyl] amino] methyl]-1,3-benzenedimethanol suitable for micronisation
CZ414899A3 (cs) Kompozice obsahující jemně rozptýlené, krystalické částice budesonidu
NZ240788A (en) 1-hydroxy-2-naphthalene carboxylate salt of 4-hydroxy- alpha 1

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20111128